

OIP  
OCT 23 2002  
PATENT & TRADEMARK

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Page 1 of 3

ATTY. DOCKET NO. PC11895A

SERIAL NO. 10/062,811

APPLICANT Thomas V. Magee, et. al.

FILING DATE January 31, 2002

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA	US	4	1	5	7	3	9	5	5 Jun 79	Hitzel, Volker, et. al.	424	266	
CA	US	4	1	8	1	6	5	8	1 Jan 80	Hitzel, Volker, et. al.	424	266	
CA	US	4	8	6	1	8	9	1	29 Aug 89	Saccomano, Nicholas A., et al	546	194	
CA	US	4	6	9	2	1	8	5	8 Sep 87	Michaely, William J.	71	94	
CA	US	5	5	5	2	4	3	8	3 Sep 96	Christensen, Siegfried B. IV	514	520	
CA	US	5	6	0	2	1	5	7	11 Feb 97	Christensen, Siegfried B. IV	514	362	
CA	US	5	6	1	4	5	4	0	25 Mar 97	Christensen, Siegfried B. IV	514	362	
CA	US	5	8	6	3	9	2	6	26 Jan 99	Christensen, Siegfried B. IV, et al	514	277	
CA	US	5	9	2	2	5	5	7	13 Jul 99	Pon, Douglas J.	435	21	
CA	US	6	3	8	0	2	1	8	30 Apr 02	Marfat, Anthony, et. al.	514	326	

TECH CENTER 1600/2900

OCT 25 2002

RECEIVED

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
CA	WO	9	8	1	8	7	9	6	7 May 98	International	C07D	471/04		
CA	WO	9	8	4	5	2	6	8	15 Oct 98	International	C07D	213/82		
CA	WO	9	9	1	8	7	9	3	22 Apr 99	International	A01N	43/38		
CA	WO	9	5	0	0	1	3	9	5 Jan 95	International	A61K	31/275		
CA	WO	9	9	2	0	6	2	5	29 Apr 99	International	C07D	473/16		
CA	WO	9	9	2	0	2	8	0	29 Apr 99	International	A61K	31/52		
CA	WO	0	1	5	7	0	2	5	9 Aug 01	International	C07D	405/12		
CA	WO	0	1	5	7	0	3	6	9 Aug 01	International	C07D	413/12		
CA	GB	2	3	2	7	6	7	5	3 Feb 99	Great Britain	C07D	213/82		
CA	EP	0	0	2	3	5	6	9	22 Jun 83	EPO	C07D	295/14		
CA	EP	0	5	5	0	9	0	0	28 Dec 92	EPO	A01N	43/40	X	
CA	EP	0	5	0	0	9	8	9	9 Dec 98	EPO	C07K	5/06		
CA	EP	0	6	6	1	2	7	4	5 Jul 95	EPO	C07D	237/14		
CA	JP	7	3	0	4	7	7	5		Japanese				X
CA	FR	2	1	4	0	7	7	2		French	C07D	29/00		X

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. PC11895A

SERIAL NO. 10/062,811

(Use several sheets if necessary)

APPLICANT Thomas V. Magee, et. al.

Page 2 of 3

FILING DATE January 31, 2002

GROUP

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA		Trophy, Theodore J. et al, "Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma," Environmental Health Perspectives, Vol. 102 Suppl. 10, Dec. 1994, pp 79-84,
CA		Duplantier, Allen J., et al., "Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [ <sup>3</sup> H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret, Journal of Medicinal Chemistry," 1996, Vol. 39, No. 1, pp 120-125
CA		Schneider, Herbert H, et al, "Discriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram," Pharmacology Biochemistry and Behavior, Vol. 50, No. 2, 1995, pp. 211-217
CA		Banner, Katherine H., et. al., "Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs," British Journal of Pharmacology, 114, 1995, pp. 93-98
CA		Barnette, Mary S., et. al., "The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig Eosinophils Is Correlated with Inhibition of Phosphodiesterase IV Catalytic Activity," The Journal of Pharmacology and Experimental Therapeutics, 273, 1995 pp. 674-679
CA		Wright, Kathryn, F., et al., "Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor," Can. J. Physiol. Pharmacol. 75, 1997, pp.1001-1008
CA		Manabe, Haruhiko, "Anti-inflammatory and Bronchodilator Properties of KF19514, a Phosphodiesterase 4 and 1 Inhibitor," European Journal of Pharmacology, 332, 1997, pp. 97-107
CA		Ukita, Tatsuzo, et. al., "Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridynaphthalene Derivatives, J. Med. Chem, 48, 1999, pp. 1088-1099
CA		Compton, CH, et. al., "The Efficacy of Ariflo™ (SB 207499, A Second Generation, Oral PDE4 Inhibitor, In Patients with COPD, Am. J. Respir. Crit. Care Med., 159, 1999
CA		Leeman, Marc M.D., et. al., "Reduction in Pulmonary Hypertension and in Airway Resistances by Enoximone (MDL 17,043) in Decompensated COPD," Chest, 91, 1987, pp. 662-6
CA		Rabe, K.F., et. al., "Identification of PDE Isozymes in Human Pulmonary Artery and Effect of Selective PDE Inhibitors," Am. J. Physiol, 266 (LCMP 10), 1994, pp. L536-L543
CA		Hughes, Bernadette, et. al., "PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs, Drug Discovery Today, Science Direct, 2(3), 1997 pp. 89-101
CA		Banner, K.H., et. al., "The Effect of Selective Phosphodiesterase Inhibitors in Comparison with other Anti-asthma Drugs on Allergen-induced Eosinophilia in Guinea-pig Airways," Pulmonary Pharmacology, 8, 1995, pp. 37-42
CA		Raeburn, David, et.al., "Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase typed IV inhibitor," Br. J. Pharmacol., 113, 1994, pp. 1423-1431
CA		Karlsson, J.A., et. al., "Anti-Inflammatory Effects of the Novel Phosphodiesterase IV Inhibitor RP 73401," Int. Arch Allergy Immunol, 107, 1995, pp. 425-426
CA		Escott, K.J., et. al., "Pharmacological Profiling of Phosphodiesterase, 4 (PDE4) Inhibitors and Analysis of the Therapeutic Ratio in Rats and Dogs, Br. J. Pharmacol, 123 (Proc suppl.) 1998 40P
CA	RECEIVED	Landells, L.J., et. al., "Oral Administration of the Phosphodiesterase (PDE) 4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-induced Cell Activation," Eur. Resp. J., 12 (Suppl. 28), 362s, 1998, P2393
CA		Gale, D.D., et. al., "Pharmacodynamic-Pharmacokinetic (PD/PK) Profile of the Phosphodiesterase (PDE)4 Inhibitor, V11294A, in Human Volunteers," Am. J. Respir. Crit Care Med., 159, A611, 1999, pp A108
CA		Montana, J., et. al., "Activity of D4418, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, Effects in Cellular and Animal Models of Asthma and Early Clinical Studies," Am. J. Respir. Crit., Care Med., 159, A108, 1999, pp A624
CA		Cavalla, D., et. al., "Activity of V11294A, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, In Cellular and Animal Models of Asthma," Am. J. Respir. Crit. Care Med. 155, 1997, pp A660
CA		Pascal, Y., et. al., "Synthesis and Structure-activity Relationships of 4-oxo-1 phenyl-3,4,5,7-Tetrahydro-[1,4]Diazepino[6,7,1-H]indolines: Novel PDE4 Inhibitors," 215 <sup>th</sup> ACS, MEDI, 50, 1998
CA		Burnouf, C., et. al., "Pharmacology of the Novel Phosphodiesterase Type 4 Inhibitor, CI-1018," 215 <sup>th</sup> ACS, MEDL 008, 1998

4/97, !disclos, 2/4

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Page 3 of 3

ATTY. DOCKET NO. PC11895A

SERIAL NO. 10/062,811

APPLICANT Thomas V. Magee, et. al.

FILING DATE January 31, 2002

GROUP

CA		Mueller, George W., et. al., "N-Phthaloyl- $\beta$ - Aryl- $\beta$ - Amino Derivatives Potent TNF- $\alpha$ And PDE4 Inhibitors, MEDI, 299, 1999
CA		Mueller, George W., et. al., "Thalidomide Analogs and PDE4 Inhibition," Bioorganic & Medicinal Chemistry Letters," 8, 1998 pp. 2669-2674
CA		Takayama, K., "Synthetic Studies on Selective Type IV Phosphodiesterase (PDE IV) Inhibitors," MEDI 245, 1997
CA		Gordon, T., et. al., "Anti-Inflammatory Effects of a PDE4 Inhibitor in a Rat Model of Chronic Bronchitis," Am. J. Respir. Crit. Care Med., 159, A33, 1999
CA		Perrier, Helene, et. al., "Substituted Furans as Inhibitors of the PDE4 Enzyme," Bioorganic & Medicinal Chemistry Letters 9, 1999, pp. 323-326
CA		Groneberg, Robert D., et. al., "Dual Inhibition of Phosphodiesterase 4 and Matrix Metalloproteinases by an (Arylsulfonyl)hydroxamic Acid Template," Journal of Medicinal Chemistry, 1999, Vol. 42, No. 4, pp. 541-544
CA		Fujimura, Masaki, et. al. Bronchoprotective Effects of KF-19514 and Cilostazol in Guinea Pigs In Vivo," European Journal of Pharmacology, 327, 1997, pp. 57-63
CA		Manabe, Haruhiko, et. al., "KF19514, a Phosphodiesterase 4 and 1 Inhibitor, Inhibits PAF-Induced Lung Inflammatory Responses by Inhaled Administration in Guinea Pigs," International Archives of Allergy-Immunology, 1997, 114, pp. 389-399
CA		Suzuki, Fumio, et. al., "New Bronchodilators, 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones," Journal of Medicinal Chemistry, 1992, Vol., 35, No. 26, pp. 4866-4874
CA		Matsuura, Akihiro, et. al., "Substituted 1,8-Naphthyridin-2(1H)-ones as Selective Phosphodiesterase IV Inhibitors," Biol. Pharm. Bull. Vol. 17(4), 1994, pp. 498-503
CA		Manabe, Haruhiko, et. al., "Pharmacological properties of a New Bronchodilator, KF17625," Jpn. J. Pharmacol., 58 (Suppl 1), 1992 pp. 238
CA		Montana, John G., et. al., "PDE4 Inhibitors: New Xanthine Analogues," Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 2925-2930
CA		Merz, Karl-Heinz, et. al., "Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth," Journal of Medicinal Chemistry, Vol. 41, No. 24, 1998, pp. 4733-4743
CA		Danhaive, P., et. al., "UCB29936, A Selective Phosphodiesterase Type IV Inhibitor; Therapeutic Potential In Endotoxic Shock," Am. J. Respir. Crit. Care Med., 159, A611, 1999
CA		Tian, Gaochao, et. al., "Dual Inhibition of Human Type 4 Phosphodiesterase Isostates by (R*,R*)-( $\pm$ )-Methyl 3-Acetyl-4-[3-(cyclopentylloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate," Biochemistry, 37(19), 1998 pp. 6894-6904
CA		Norman, Peter, "PDE4 Inhibitors 1999," Exp. Opin. Ther. Patents 9(8) 1999, pp. 1101-1118
CA		Dyke, Hazel J. & Montana, John G., "The Therapeutic Potential of PDE4 Inhibitors," Expert Opinion on Investigational Drugs, 8(9), 1999, pp. 1301-1325
CA		XP-002066969, Vinivk, Fredric J., et. al., "Nicotinamide Ethers: Novel Inhibitors of Calcium-Independent Phosphodiesterase and [3H]Rolipram Binding," Journal of Medicinal Chemistry, Vol. 34, No. 1., 1991, pp. 86-89
CA		Pruniaux, M.P., et. al., "The novel phosphodiesterase 4 inhibitor CI-1018 inhibits antigen-induced lung eosinophilia in sensitized brown-norway rats - comparison with rolipram," Mediators of Inflammation, Vol. 8, Supplement 1, 1999, S-04-6, pp. S10

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4/97, !disclos, 3/4